Fiserv's recent 'strategic reset' was a necessary response to the previous CEO juicing short-term profits by gutting customer-facing roles. The client support team for major accounts like DoorDash and eBay was cut to just two people, causing service to collapse and forcing the new CEO to reinvest heavily.

Most turnarounds fail. Instead of investing on the announcement, wait 12-24 months for early evidence in leading KPIs before they hit the bottom line. This improves your odds, as turnarounds that start working rarely revert. The probability gain is worth more than the initial upside you miss.

In biotech, CEO insider buys are common and not very predictive. The real signal comes from the rest of the management team, especially the CFO. CFOs are typically more bearish and financially disciplined, so their decision to buy company stock is a particularly strong vote of confidence.

A CFO's large personal investment, despite a significant subsequent stock price decline, indicates strong belief in a turnaround. Newell's strategy of cutting unprofitable product lines to boost profitability is being misread by the market as just falling revenue, creating a potential value opportunity.

The dramatic shift in Fiserv's CEO approval rating on Glassdoor from a toxic 12% under the prior CEO to 71% under the new one is a powerful leading indicator. This rapid improvement in morale and culture suggests a business turnaround is underway, long before it will be reflected in financial reports.

Fiserv's turnaround is being driven by a massive influx of top-tier talent, led by legendary COO Takis Chakakopoulos from JPMorgan. He has attracted a wave of high-performers from JPMorgan and Stripe, an 'Avengers Assemble' moment that the market has largely missed.

Insider buying in biotech isn't just a short-term trading signal around an event. The quantitative analysis shows its predictive power lasts for months after the transaction. This implies insiders are buying based on a durable, fundamental belief in the company's science and trajectory, not just upcoming news.

Warren Buffett's successor, Greg Abel, is investing his entire $15 million salary into Berkshire Hathaway stock. This is a powerful form of "eating your own dog food" that signals ultimate confidence in the company's future to the market, aligning his personal financial success directly with shareholder outcomes.

Insiders and CEOs are generally good at timing capital allocation, issuing shares when prices are high and buying back when low. The current lack of equity issuance from high-flying tech companies suggests their leadership doesn't view their stock as overvalued, despite having clear reasons to raise capital.